Advertisement

Topics

Siamab Therapeutics Announces Publication of New Preclinical Data in the Journal mAbs Describing its Novel Monoclonal Antibody Approach to Targeting the Tumor-Associated Carbohydrate Antigen STn

08:01 EST 8 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Findings Show ST1 Antibodies and Antibody Drug Candidates Demonstrated Efficacy and Tumor Growth Inhibition in Breast and Colorectal Cancer Models Siamab Therapeutics, Inc., a biopharmaceutical company developing novel ...

Other Sources for this Article

Corporate Contact:
Siamab Therapeutics
Jenna Stein, 857-222-5817
jenna@siamab.com
or
Media Contact:
Rozen Communications
Michele Rozen, 617-730-8284
michele@rozencommunications.com

NEXT ARTICLE

More From BioPortfolio on "Siamab Therapeutics Announces Publication of New Preclinical Data in the Journal mAbs Describing its Novel Monoclonal Antibody Approach to Targeting the Tumor-Associated Carbohydrate Antigen STn"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...